http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 28 Sep 2026 16:36:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vogenx%2C+Inc.++++++++++++++For%3A+Sep+21++Filed+by%3A+Toombs+Kenneth+John/27115055.html si-local-file:///var/storage/secattach/20260928/27115055.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vogenx%2C+Inc.++++++++++++++For%3A+Sep+21++Filed+by%3A+Toombs+Kenneth+John/27115055.html Mon, 28 Sep 2026 16:36:00 -0400 VOGX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vogenx%2C+Inc.++++++++++++++For%3A+Sep+21/27090982.html si-local-file:///var/storage/secattach/20260922/27090982.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vogenx%2C+Inc.++++++++++++++For%3A+Sep+21/27090982.html Tue, 22 Sep 2026 16:01:00 -0400 VOGX http://www.streetinsider.com/Board+Changes/Vogenx+adds+consulting+veteran+Ken+Toombs+to+its+board/27088688.html <p>Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage biopharmaceutical company based in Raleigh, North Carolina, has appointed Ken Toombs to its Board of Directors, effective September 21, 2026. Toombs will serve as an independent director and Chair of the Audit Committee, according to a company statement.</p> <p>Toombs brings roughly 30 years of experience in the professional services industry. He most recently served as Chief Executive Officer of PA Consulting, a London-based consultancy, a role he assumed in October 2020 after joining the firm in 2018 to lead its Americas business. He previously served as Global Head of Infosys Consulting, Deputy Chief Executive Officer http://www.streetinsider.com/Board+Changes/Vogenx+adds+consulting+veteran+Ken+Toombs+to+its+board/27088688.html Tue, 22 Sep 2026 09:01:41 -0400 VOGX http://www.streetinsider.com/Press+Releases/Vogenx+Appoints+Ken+Toombs+to+Board+of+Directors/27088625.html <p><strong id="dateline">RALEIGH, NC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong><strong>Vogenx, Inc. </strong>(Nasdaq:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced the appointment of Ken Toombs to its Board of Directors, effective September 21, 2026. Mr. Toombs will serve as an independent director and as Chair of the Audit Committee.</p><p>Mr. Toombs is a thirty-year veteran of the global professional services industry, most recently serving as Chief Executive Officer of PA Consulting, the London-headquartered innovation and transformation consultancy. He joined PA Consulting in 2018 http://www.streetinsider.com/Press+Releases/Vogenx+Appoints+Ken+Toombs+to+Board+of+Directors/27088625.html Tue, 22 Sep 2026 09:00:00 -0400 VOGX http://www.streetinsider.com/ACCESS+Newswire/Vogenx+Appoints+Ken+Toombs+to+Board+of+Directors/27088625.html <p><strong id="dateline">RALEIGH, NC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong><strong>Vogenx, Inc. </strong>(Nasdaq:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced the appointment of Ken Toombs to its Board of Directors, effective September 21, 2026. Mr. Toombs will serve as an independent director and as Chair of the Audit Committee.</p><p>Mr. Toombs is a thirty-year veteran of the global professional services industry, most recently serving as Chief Executive Officer of PA Consulting, the London-headquartered innovation and transformation consultancy. He joined PA Consulting in 2018 http://www.streetinsider.com/ACCESS+Newswire/Vogenx+Appoints+Ken+Toombs+to+Board+of+Directors/27088625.html Tue, 22 Sep 2026 09:00:00 -0400 VOGX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vogenx%2C+Inc.++++++++++++++For%3A+Jun+30/27076182.html si-local-file:///var/storage/secattach/20260917/27076182.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Vogenx%2C+Inc.++++++++++++++For%3A+Jun+30/27076182.html Thu, 17 Sep 2026 16:24:00 -0400 VOGX http://www.streetinsider.com/New+Coverage/WBB+Securities+Starts+Vogenx+%28VOGX%29+at+Speculative+Buy/27017098.html <p>WBB Securities analyst Steve Brozak initiates coverage on Vogenx (NASDAQ: VOGX) with a Speculative Buy rating.</p><p>For an analyst ratings summary and ratings history on Vogenx <a href="http://www.streetinsider.com/rating_history.php?q=VOGX">click here</a>. For more ratings news on Vogenx <a href="http://www.streetinsider.com/stock_lookup_news.php?q=VOGX&amp;type=analyst">click here</a>.</p><p>Shares of Vogenx closed at $33.13 yesterday.</p> http://www.streetinsider.com/New+Coverage/WBB+Securities+Starts+Vogenx+%28VOGX%29+at+Speculative+Buy/27017098.html Wed, 02 Sep 2026 10:30:55 -0400 VOGX http://www.streetinsider.com/New+Coverage/Jones+Trading+Starts++Vogenx+%28VOGX%29+at+Buy/27005782.html <p>Jones Trading analyst Catherine Novack initiates coverage on Vogenx (NASDAQ: VOGX) with a Buy rating and a price target of $55.00.</p><p> </p> http://www.streetinsider.com/New+Coverage/Jones+Trading+Starts++Vogenx+%28VOGX%29+at+Buy/27005782.html Mon, 31 Aug 2026 16:11:36 -0400 VOGX http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/IPOs/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html <p>Vogenx, Inc. (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on therapeutics for diseases related to human metabolism dysfunction, completed an $81.3 million initial public offering on Aug. 13, 2026, according to a press release from JonesTrading Institutional Services LLC.</p> <p>The offering consisted of 6,250,000 shares of common stock priced at $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds, before underwriting discounts, commissions, and other expenses, totaled approximately $81.3 million.</p> <p>JonesTrading served as the sole book-running manager for the transaction. Vogenx's shares began trading on the Nasdaq Capital Market on Aug. 12, http://www.streetinsider.com/Equity+Offerings/Vogenx+raises+%2481.3M+in+Nasdaq+IPO+managed+by+JonesTrading/26936940.html Mon, 17 Aug 2026 12:26:18 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/Press+Releases/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020248705" idsrc="xmltag.org" >JonesTrading Institutional Services LLC</span> ("Jones") today announced that it served as sole book-running manager for the <money>$81.3 million</money> initial public offering of <span value="ACORN:5021697153" idsrc="xmltag.org" >Vogenx, Inc.</span> (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html Mon, 17 Aug 2026 12:25:00 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/PRNewswire/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020248705" idsrc="xmltag.org" >JonesTrading Institutional Services LLC</span> ("Jones") today announced that it served as sole book-running manager for the <money>$81.3 million</money> initial public offering of <span value="ACORN:5021697153" idsrc="xmltag.org" >Vogenx, Inc.</span> (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html Mon, 17 Aug 2026 12:25:00 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/Press+Releases/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020248705" idsrc="xmltag.org" >JonesTrading Institutional Services LLC</span> ("Jones") today announced that it served as sole book-running manager for the <money>$81.3 million</money> initial public offering of <span value="ACORN:5021697153" idsrc="xmltag.org" >Vogenx, Inc.</span> (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html Mon, 17 Aug 2026 12:25:00 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/PRNewswire/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020248705" idsrc="xmltag.org" >JonesTrading Institutional Services LLC</span> ("Jones") today announced that it served as sole book-running manager for the <money>$81.3 million</money> initial public offering of <span value="ACORN:5021697153" idsrc="xmltag.org" >Vogenx, Inc.</span> (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html Mon, 17 Aug 2026 12:25:00 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/Press+Releases/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020248705" idsrc="xmltag.org" >JonesTrading Institutional Services LLC</span> ("Jones") today announced that it served as sole book-running manager for the <money>$81.3 million</money> initial public offering of <span value="ACORN:5021697153" idsrc="xmltag.org" >Vogenx, Inc.</span> (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html Mon, 17 Aug 2026 12:25:00 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/PRNewswire/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020248705" idsrc="xmltag.org" >JonesTrading Institutional Services LLC</span> ("Jones") today announced that it served as sole book-running manager for the <money>$81.3 million</money> initial public offering of <span value="ACORN:5021697153" idsrc="xmltag.org" >Vogenx, Inc.</span> (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html Mon, 17 Aug 2026 12:25:00 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX http://www.streetinsider.com/Press+Releases/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>Aug. 17, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:5020248705" idsrc="xmltag.org" >JonesTrading Institutional Services LLC</span> ("Jones") today announced that it served as sole book-running manager for the <money>$81.3 million</money> initial public offering of <span value="ACORN:5021697153" idsrc="xmltag.org" >Vogenx, Inc.</span> (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Jones+Served+as+Sole+Book-Running+Manager+for+Vogenx%27s+%2481.3+Million+Initial+Public+Offering/26936938.html Mon, 17 Aug 2026 12:25:00 -0400 A.50202487 A.50216971 O.51469867 O.53171562 VOGX